Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634959 · ClinicalTrials.gov registry record · Phase 2
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00634959 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 37 participants.
The verdict
NCT00634959, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
Interventions
- OTHER Placebo
- DRUG Maraviroc (UK-427,857)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2003-07 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634959
The ClinicalTrials.gov registry entry for NCT00634959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00634959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634959 about?
NCT00634959 is a clinical study titled "Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus". To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
What is the current status of trial NCT00634959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2003-07. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00634959?
The interventions under investigation include: Placebo (OTHER), Maraviroc (UK-427,857) (DRUG).
Who is sponsoring clinical trial NCT00634959?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.